Phase I/II Study of Polyphenon E in Addition to Erlotinib in Advanced Non Small Cell Lung Cancer
Phase of Trial: Phase I/II
Latest Information Update: 28 Apr 2015
At a glance
- Drugs Polyphenon E (Primary) ; Erlotinib
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- 10 Jun 2017 Biomarkers information updated
- 30 Dec 2014 Protocol has been amended to change in primary outcome, inclusion criteria and treatment arms.
- 30 Dec 2014 Status changed from completed to discontinued as reported by ClinicalTrials.gov record.